Related Experiment Videos
Opioid gene expression in rat striatum is modulated via opioid receptors: evidence from localized receptor
1Department of Neuropharmacology, Max-Planck-Institut für Psychiatrie, Planegg-Martinsried F.R.G.
Abstract:
The irreversible opiate antagonists beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) were injected into rat striatum. One day later, mu-opioid receptor binding, as assessed by receptor autoradiography, was abolished in the injected striatum, while [3H]spiperone binding remained largely unaffected. In situ hybridization was used to examine possible effects on striatal proenkephalin mRNA and prodynorphin mRNA content. The levels of proenkephalin mRNA were increased ipsilaterally following beta-CNA injection, but were slightly decreased following beta-FNA injection. Prodynorphin mRNA content was also increased by beta-CNA administration. The results provide evidence for a differential modulation of striatal opioid peptide gene expression via distinct opioid receptors.
Insights
Irreversible opiate antagonists beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) differentially affect opioid peptide gene expression in rat striatum. These findings suggest distinct opioid receptors modulate striatal proenkephalin and prodynorphin mRNA levels.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Opioid receptors play a crucial role in regulating various physiological processes.
- Understanding the specific roles of different opioid receptor subtypes is essential for developing targeted therapies.
- The striatum is a key brain region involved in motor control, reward, and habit formation, with significant opioid peptide expression.
Purpose of the Study:
- To investigate the effects of irreversible mu-opioid receptor antagonists on opioid peptide gene expression in the rat striatum.
- To determine if different opioid receptor antagonists differentially modulate proenkephalin and prodynorphin mRNA levels.
- To elucidate the role of distinct opioid receptors in regulating striatal opioid peptide synthesis.
Main Methods:
- Administration of irreversible opiate antagonists beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) into the rat striatum.
- Assessment of mu-opioid receptor binding using receptor autoradiography one day post-injection.
- Quantification of striatal proenkephalin mRNA and prodynorphin mRNA levels using in situ hybridization.
Main Results:
- Mu-opioid receptor binding was abolished in the striatum following antagonist injection, while [3H]spiperone binding was unaffected.
- Beta-chlornaltrexamine (beta-CNA) administration increased both proenkephalin and prodynorphin mRNA levels in the striatum.
- Beta-funaltrexamine (beta-FNA) injection led to a slight decrease in proenkephalin mRNA levels.
Conclusions:
- The study demonstrates differential modulation of striatal opioid peptide gene expression by distinct opioid receptors.
- These findings highlight the specific roles of mu-opioid receptor subtypes in regulating proenkephalin and prodynorphin synthesis.
- The results provide valuable insights into the complex opioidergic system within the striatum and its potential therapeutic implications.